News for hackers. Stuff that matters.
Re:Coronavirus human challenge study gets green light in UK by mjmahone17 on Wednesday February 17, 2021 @02:42PM (#26170624)
> And what exactly would that have told you about the safety and effectiveness of the vaccine for the people at risk, those who are neither young nor healthy?

So if the goal was to reduce transmission, you can save a lot of lives of those at risk by vaccinating the young and healthy. It would be reasonable to basically use challenge studies to get a lower transmission rate, while in parallel using standard trials to prove the efficacy in at risk populations.

Getting more data quicker is usually a good way to make more informed decisions, even if the data isn’t exactly what you want it to be to make the perfectly optimal choices.

Re:Coronavirus human challenge study gets green light in UK by runako on Wednesday February 17, 2021 @03:32PM (#26171330)
> So if the goal was to reduce transmission, you can save a lot of lives of those at risk by vaccinating the young and healthy.

Has this been tested yet? Is there evidence that this is true beyond the broad population surveys like those from Israel? (The accuracy of those data were hotly debated here last week.)

Surely a study to determine actual transmission rates would be much more complex than one to determine whether young & healthy people are infected after inoculation (which again: not that useful of a data point by itself)?

Re:Coronavirus human challenge study gets green light in UK by graeme on Wednesday February 17, 2021 @04:35PM (#26172104)
Every vaccine we have developed in the past had reduced transmission. No exceptions. It is scientific blindness to abandon all of our priors and say “who knows if it reduces transmission?”
Re:Coronavirus human challenge study gets green light in UK by oldgradstudent on Wednesday February 17, 2021 @04:49PM (#26172271)
There are exceptions.

The Tetanus vaccine targets the toxin, not the pathogen.

Some research may indicate that the current a-cellular whooping cough vaccine prevents symptoms, but not transmission. The older vaccine prevented transmission, but had too many side effects.

The oral polio vaccine may actually result in outbreaks of the vaccine strain.

http://www.emro.who.int/syr/syria-news/polio-outbreak-succes...

Claims about prevention of transmission needs to be demonstrated in a trial, not simply asserted.

Re:Coronavirus human challenge study gets green light in UK by maxerickson on Wednesday February 17, 2021 @05:12PM (#26172511)
So would you expect a vaccine that is targeted at a viral protein to target something other than the viral protein?
Re:Coronavirus human challenge study gets green light in UK by oldgradstudent on Wednesday February 17, 2021 @05:25PM (#26172639)
I have no idea. But I see no reason to a-priori assume perfect targeting without a trial.

Supposedly, the Pandemrix fiasco happened because the antibodies generated by the vaccine cross reacted with some human proteins.

The lengthy drug approval regimen exists not because of some power drunk bureaucrats. It exists because of a long history of dangerous and ineffective drugs that looked really great in theory.

Re:Coronavirus human challenge study gets green light in UK by graeme on Wednesday February 17, 2021 @05:52PM (#26172917)
The antibodies in pandremix would have had the same effect had those who were vaccinated been infected by the flu instead, except the narcolepsy would have been worse.
Re:Coronavirus human challenge study gets green light in UK by oldgradstudent on Wednesday February 17, 2021 @06:12PM (#26173129)
Or another, safer, vaccine could have been used instead.
Re:Coronavirus human challenge study gets green light in UK by maxerickson on Wednesday February 17, 2021 @06:32PM (#26173328)
I was more ragging on the tetanus paragraph.
Re:Coronavirus human challenge study gets green light in UK by graeme on Wednesday February 17, 2021 @05:36PM (#26172740)
Tetanus does not transmit person to person and so is a poor example. In particular since the coronavirus vaccines do target the pathogen.

Likewise, it is not surprising that injecting a live polio virus can cause an infection. That is a different claim than saying a vaccinated person will get infected and transmit later once immune. Further, the coronavirus vaccines do not use live viruses.

Whooping cough is the example people love to bring up. I’ll paste in full my prior comment on this. The worst case example reduces transmission at least 30%! And probably more: it was completely sterilizing in 30% but may well have reduced transmissibility in other groups. And that’s the very worst case vaccine.

———————-

I looked into this, and it does seem the vaccine reduces transmission. It just doesn’t stop it entirely. The paper below is Wikipedia’s source. Upon a close read, in the daycare there were three groups of vaccinated children: * Those positive for antibodies but pcr negative —> had been exposed, cleared virus without infection * those pcr positive but asymptomatic * those pcr positive and symptomatic About 30% were in the seropositive group which didn’t have pcr positivity. So it seems like transmission was reduced at least 30%. It’s also possible the other two groups would have had lower transmission rates than if they had had no vaccine. If you have a more precise source I’d be interested to see it, but if this is the worst case it’s pretty good! > We used PCR, EIA, and culture to confirm B. pertussis infection in two highly vaccinated groups of children in two day-care centers. Three (10%) of 30 2- to 3-year-old children were seropositive for recent infection; one had nasopharyngeal colonization and a clinical illness that met the modified WHO case definition. In the day-care center for the 5- to 6- year-old group, 9 (55%) of 16 children were IgM positive, 4 (25%) of whom had nasopharyngeal colonization. Of these four children, three had nonspecific cough, and only one met the modified WHO definition for pertussis. None of the children in our study, including those who met the WHO definition, had been examined by a physician before our investigation. >Children who were seropositive and re- mained both asymptomatic and PCR negative probably had sufficient immunity from vaccines or natural boosters to protect them against persistent colonization and clinical disease. Their seropositivity could not be due to vaccine because the children were tested more than a year after having been vaccinated.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627963/pdf/109...

https://news.ycombinator.com/item?id=25903787

Re:Coronavirus human challenge study gets green light in UK by oldgradstudent on Wednesday February 17, 2021 @06:07PM (#26173091)
I am not sure how do you draw these conclusions from the study.

There's no comparison between transmission by vaccinated and non-vaccinated children, so there's no possible way of concluding that vaccination reduced transmission relative to non-vaccination.

Re:Coronavirus human challenge study gets green light in UK by graeme on Wednesday February 17, 2021 @06:17PM (#26173175)
Among the vaccinated students 30% showed antibodies but were pcr negative. Hence they had fought off an infection but had no trace of replication.

You would not expect to see seropositive but pcr negative students if unvaccinated.

Re:Coronavirus human challenge study gets green light in UK by runako on Wednesday February 17, 2021 @04:40PM (#26172152)
I'm not suggesting we abandon priors, but Covid does have some novel facts:

- apparently high asymptomatic rate

- somewhat unpredictable who will get severe case

- random neurological symptoms in a respiratory virus

And most/all of the vaccines we are using will be the first approved for human use on their respective platforms. It's worth looking at.

Also, for a pathogen that is so highly transmissible, it's worth understanding what we mean by "reduced transmission". Is it 10% less? 90%? Surely this would be important to know before following a strategy of vaccinating the young and healthy first. (Especially given the difficulty of doing so in a population that is least likely to suffer serious harm from the pathogen.)

Re:Coronavirus human challenge study gets green light in UK by graeme on Wednesday February 17, 2021 @05:51PM (#26172903)
The point is we could have vaccinated the young and healthy summer 2020, had we had challenge trials proving efficacy in that group. How could that not have helped?

We vaccinated no one in that period as it is.

Re:Coronavirus human challenge study gets green light in UK by runako on Wednesday February 17, 2021 @06:39PM (#26173414)
Even a challenge trial would need to be run properly and include enough people to generate useful data. But let's play the opposite. Let's be unscientific and assume an untested vaccine on a novel platform would reduce transmission risk (Edit: if we assume this, why not just assume the candidate vaccine works and just skip the challenge trials too?). Further assume that recruiting enough volunteers for meaningful results would be easy in spring 2020, before the age cohort differences in severity were as established.

Given those assumptions, there still needs to be a smaller safety trial before a large challenge trial. BioNTech started those in April, that ended in May. Deployment in the summer is already aggressive, assuming no challenge trials and we had just deployed vaccines shown to be safe in very small trials.

But suppose a challenge trial was run rapidly over the next three months (to determine which of the BioNTech candidates was best). Assume this all goes optimally. This plan still assumes the existence of scale manufacturing facilities that likely did not exist last summer. Let's wish that away too, so we have scaled manufacturing capacities to June 2021 levels by May 2020. While we have our magic wand out, let's wave away the fact that the vaccine initially took over 100 days to manufacture, so that in our world we can decide what to produce today and have it ready tomorrow instead of next quarter. So we've got positive challenge trial results in July 2020 with faster-than-2021 production capacity to go to scale.

Now, perception-wise, we are asking young healthy people to take a vaccine designed on a novel platform that was rushed through a novel ethics-skirting approval process, for a virus that likely won't seriously harm them if they get it. I'm not sure that would be as effective as people seem to think it is.

Re:Coronavirus human challenge study gets green light in UK by tinus_hn on Wednesday February 17, 2021 @05:53PM (#26172932)
We didn’t even bother manufacturing vaccines. Even though they were paid in advance.
Re:Coronavirus human challenge study gets green light in UK by graeme on Wednesday February 17, 2021 @06:18PM (#26173180)
Because there was no one approved to give them to. Companies could have gone some out if govts had ordered delivery earlier for the age groups in question.

It would have sped up subsequent production too.

Re:Coronavirus human challenge study gets green light in UK by tinus_hn on Wednesday February 17, 2021 @07:33PM (#26173874)
The orders were placed and guaranteed over half a year ago. Don’t make up excuses.
Re:Coronavirus human challenge study gets green light in UK by Closi on Wednesday February 17, 2021 @03:38PM (#26171408)
Well transmission effectiveness is a good example of something that’s much easier to measure in a controlled challenge study and almost impossible to measure pre-rollout without it!
Re:Coronavirus human challenge study gets green light in UK by runako on Wednesday February 17, 2021 @03:48PM (#26171524)
How? The vaccinated individuals would come into contact with lots of people who are not vaccinated. How do you track all of them to determine if vaccinated individuals can transmit the disease? That seems like a much larger logistical problem that differs from the existing (and challenge) trials in very material ways.
Re:Coronavirus human challenge study gets green light in UK by Closi on Wednesday February 17, 2021 @03:55PM (#26171639)
Well you observe transmission within a controlled environment - ie you keep people in the lab and don’t let them go home.

You could take 50 people, vaccinate half and give half a placebo, infect them with Covid, then put them in 50 rooms with 50 other unvaccinated people (so each has two people) for 2 weeks and see what happens.

The reason you can’t do it without a challenge trial is exactly because of what you said - you can’t track infections in the community.

Re:Coronavirus human challenge study gets green light in UK by runako on Wednesday February 17, 2021 @04:21PM (#26171957)
I wonder how big such a trial would need to be in order to generate any meaningful confidence in the results, especially given the unpredictability of this pathogen.

Also note that had this been run last spring you've doubled the size of the trial and therefore the number of hospitalized patients who would not have life-saving therapeutics. By comparison, the BioNTech/Pfizer vaccine had over 40,000 people in its trial. Not sure you could even run a trial that big with even a tenth as many people.

Re:Coronavirus human challenge study gets green light in UK by Closi on Wednesday February 17, 2021 @04:31PM (#26172064)
You should need less people in a challenge trial - the reason 40,000 was so high is because only a small amount of those people was expected to be infected, e.g. maybe only a few hundred of those actually got infected even in the control group. (Eg in a control group of 20k maybe 1% got infected = 200 people).

In a challenge trial you can make people cough in each other’s faces, or literally inject them with Covid depending on the study, which raises your chance of getting people infected and seeing the impact. You would expect the control group to have a very high infection rate, and to see the difference in the study group much more easily.

I’m not saying 100 people would be enough, but you would need significantly fewer people fewer to get a good level of confidence.

Re:Coronavirus human challenge study gets green light in UK by runako on Wednesday February 17, 2021 @04:55PM (#26172328)
You need a lot of participants because the expected outcome is that you inject a novel foreign substance into billions of people. At some point, you have to test for safety too, and very small trials are not good for that.

And again -- the backup therapeutics that enable any challenge trial were not broadly available until a month or two before vaccines went into wide deployment. (You will note that nobody is volunteering for a challenge trial for any drugs or vaccines for our other ongoing pandemic, HIV. Lack of backup therapeutics is a big reason for that.)

Re:Coronavirus human challenge study gets green light in UK by Closi on Wednesday February 17, 2021 @05:29PM (#26172676)
You still need to test for safety, that's definitely true. At least you know you have a viable candidate though I guess.

People were actually volunteering for a challenge trial for Covid prior to theraputics being available - because Covid actually is low-risk for the groups in the challenge trial (young people) and the vast majority of people recover. I don't think theraputics are necessary for a challenge trial, as long as there is sufficient benefit, the risk is sufficiently low, and volunteers are aware of the personal risks (aware this criteria is ambiguous!).

HIV is incurable, however there are excellent therapeutics. Despite this, the prognosis of HIV is much worse than someone with Covid.

Re:Coronavirus human challenge study gets green light in UK by sudosysgen on Wednesday February 17, 2021 @04:32PM (#26172086)
You can't measure immediate response. You'd have to wait 3-6 weeks to see if protection against transmission still works. It would be maybe a 2-3 weeks faster but not yield as useful of data.